Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

13.57 -0.05 (-0.37%)

Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Biohaven Stock Crushed it on Monday ↗

April 13, 2026

The biotech was boosted by an analyst's initiation of coverage.

Via The Motley Fool

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

Biohaven Ltd. (NYSE:BHVN) Posts Narrower-Than-Expected Q4 2025 Loss Amid Clinical Progress ↗

March 02, 2026

Via Chartmill

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗

March 09, 2026

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.

Via Stocktwits

SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗

March 03, 2026

SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗

March 03, 2026

This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers.

Via The Motley Fool

Topics Regulatory Compliance

Wondering what's happening in today's after-hours session? ↗

January 26, 2026

Via Chartmill

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...

Via PredictStreet

Topics Economy Intellectual Property

Stay updated with the stocks that are on the move in today's pre-market session. ↗

December 26, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

Biohaven’s Phase II Depression Trial Falls Short, But Analysts Downplay Impact – Wall Street Looks Ahead To Epilepsy Data ↗

December 26, 2025

William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects.

Via Stocktwits

Topics Artificial Intelligence

Thursday's after hours session: top gainers and losers ↗

December 25, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Which stocks are moving after the closing bell on Wednesday? ↗

December 24, 2025

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts ↗

December 24, 2025

The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo.

Via Stocktwits

Biohaven Insiders Bet $33 Million on a Turnaround ↗

November 20, 2025

Via MarketBeat

Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? ↗

November 19, 2025

The Chief Accounting Officer added to his more than 85,000 shares held.

Via The Motley Fool

Topics Regulatory Compliance

Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake? ↗

November 19, 2025

The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.

Via The Motley Fool

FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 12, 2025

Via Benzinga

Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

November 12, 2025

Via Benzinga

These stocks are moving in today's session ↗

November 05, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection ↗

November 05, 2025

Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.

Via Benzinga

Keep an eye on the top gainers and losers in Wednesday's session. ↗

November 05, 2025

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

Crude Oil Down 1%; Solid Power Shares Spike Higher ↗

November 05, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

November 05, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Dow Surges 100 Points; McDonald's Posts Downbeat Earnings ↗

November 05, 2025

Via Benzinga

Topics Stocks

Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug ↗

November 05, 2025

The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke.

Via Investor's Business Daily

Topics Earnings

Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Wednesday. ↗

November 05, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.